E C Besa, D Klumpe. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Agammaglobulinemia/therapyCost-Benefit AnalysisHumansImmunization, Passive/economicsInfection Control/economicsLeukemia, Lymphocytic, Chronic, B-Cell/complications
Year: 1992 PMID: 1727232 DOI: 10.1056/NEJM199201093260216
Source DB: PubMed Journal: N Engl J Med ISSN: 0028-4793 Impact factor: 91.245